FN2 Earnings Intelligence
Medtronic plc earnings overview
Latest Medtronic plc (MDT) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
Medtronic plc
The quarter supports a constructive growth case: management reported broad platform momentum, raised FY27 guidance, and described margin-improvement progress. The evidence is encouraging but partly reflects an extra selling week, while execution, mix, foreign exchange, and separation-related risks remain unresolved.
Medtronic plc
Medtronic closed fiscal 2026 with its strongest top-line performance in a decade — $9.8B in Q4 revenue, up 9.9% YoY, and $36.4B for the full year. Cardiac Ablation Solutions (CAS) crossed $2B annualized with 78% global growth, solidifying it as the company's lead growth engine. The MiniMed diabetes business completed its IPO spin-off, streamlining the portfolio toward higher-margin platforms. Management raised FY27 guidance to 6.75–7.25% organic revenue growth and EPS of $5.90–$6.00, stepping up from the prior quarter's qualitative 'high-single-digit EPS growth' framing. The diversified growth platform — CAS, Symplicity renal denervation, Hugo surgical robotics, Altaviva, and Stealth AXiS — is delivering, though tariff exposure has grown and TAVR remains a soft spot.
Medtronic plc
The supplied evidence supports a constructive but execution-dependent view: strong Cardiac Ablation Solutions growth and several newly cleared or expanding platforms improve the medium-term growth case, while maintained guidance, tariff exposure, mix dilution, and adoption risks argue against treating the trajectory as assured.
Medtronic plc
The quarter supports a constructive operating thesis for Medtronic: reported growth and raised guidance were supported by PFA cardiac ablation, while Simplicity and Altaviva broadened the growth pipeline. The thesis remains dependent on manufacturing scale, payer adoption, regulatory execution, and margin control.
Medtronic plc
The quarter provided support for a growth-and-execution case: revenue growth, an EPS beat and higher guidance were accompanied by strong CAS momentum. The thesis still depends on converting upcoming product launches and the MiniMed separation into durable growth and margin improvement while managing tariffs and mix.
Medtronic plc
The call supports a constructive operating thesis: resilient demand and a portfolio of growth initiatives may support medium-term expansion, while the diabetes separation could improve margins and EPS. That case remains conditional on tariff mitigation, regulatory progress, back-loaded execution, and successful separation mechanics.
Get the MDT recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.